Prostaglandin E2 Prevents Radiotherapy-Induced Alopecia by Attenuating Transit Amplifying Cell Apoptosis Through Promoting G1 Arrest
Studysummary This study found that local PGE2 injection may prevent radiotherapy-induced hair loss by protecting hair follicle cells and promoting hair follicle self-repair. Our plain-language summary of this paper — not a Tressless recommendation.
The study investigates the effect of Prostaglandin E2 (PGE2) on preventing radiotherapy-induced alopecia (RIA). Researchers found that local cutaneous PGE2 injections reduced hair loss by preventing the premature termination of the hair follicle (HF) growing phase (anagen) and enhancing HF self-repair. PGE2 preserved more transit amplifying cells (TACs) by transiently arresting them in the G1 phase, reducing TAC apoptosis and mitigating HF dystrophy. This preservation accelerated HF self-repair and bypassed RT-induced premature anagen termination. Additionally, systemic administration of PD0332991, a CDK4/6 inhibitor, showed similar protective effects. Thus, PGE2 has potential as a local preventive treatment for RIA by promoting G1 arrest and accelerating HF regeneration.
